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Abstract
We showed previously that the attachment of synovial fibroblasts to laminin (LM)-111 in the presence
of transforming growth factor-beta induces significant expression of the matrix metalloproteinase
(MMP)-3. Here we go on to investigate the regulation of additional MMPs and their specific tissue
inhibitors of matrix proteases (TIMPs). Changes in steady-state mRNA levels encoding TIMPs and
MMPs were investigated by quantitative reverse transcription-polymerase chain reaction. Production of
MMPs was monitored by a multiplexed immunoarray. Signal transduction pathways were studied by
immunoblotting. Attachment of synovial fibroblasts to LM-111 in the presence of transforming growth
factor-beta induced significant increases in MMP-3 mRNA (12.35-fold, p < 0.001) and protein (mean 62
ng/ml, sixfold, p < 0.008) and in expression of MMP-10 mRNA (11.68-fold, p < 0.05) and protein (54
ng/ml, 20-fold, p > or = 0.02). All other TIMPs and MMPs investigated failed to show this
LM-111-facilitated transforming growth factor-beta response. No phosphorylation of nuclear
factor-kappaB was observed. We conclude that co-stimulation of synovial fibroblasts by LM-111
together with transforming growth factor-beta suffices to induce significant expression of MMP-3 and
MMP-10 by synovial fibroblasts and that this induction is independent of nuclear factor-kappaB
phosphorylation.
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ABSTRACT
We showed previously that the attachment of synovial
fibroblasts to laminin (LM)-111 in the presence of
transforming growth factor-b induces significant expres-
sion of the matrix metalloproteinase (MMP)-3. Here we
go on to investigate the regulation of additional MMPs
and their specific tissue inhibitors of matrix proteases
(TIMPs). Changes in steady-state mRNA levels encoding
TIMPs and MMPs were investigated by quantitative
reverse transcription–polymerase chain reaction.
Production of MMPs was monitored by a multiplexed
immunoarray. Signal transduction pathways were studied
by immunoblotting. Attachment of synovial fibroblasts to
LM-111 in the presence of transforming growth factor-b
induced significant increases in MMP-3 mRNA (12.35-
fold, p,0.001) and protein (mean 62 ng/ml, sixfold,
p,0.008) and in expression of MMP-10 mRNA (11.68-
fold, p,0.05) and protein (54 ng/ml, 20-fold, p>0.02).
All other TIMPs and MMPs investigated failed to show
this LM-111-facilitated transforming growth factor-b
response. No phosphorylation of nuclear factor-kB was
observed. We conclude that co-stimulation of synovial
fibroblasts by LM-111 together with transforming growth
factor-b suffices to induce significant expression of MMP-
3 and MMP-10 by synovial fibroblasts and that this
induction is independent of nuclear factor-kB phosphor-
ylation.
The elevated expression of matrix-degrading pro-
teases in synovial lining cells contributes to the
destruction of cartilage and bone. Overexpression
of these proteases is activated by a variety of
cytokines, such as interleukin (IL)-1b or tumour
necrosis factor (TNF)-a 1 and other factors.2 We
showed previously that stimulation of synovial
fibroblasts (SF) by transforming growth factor
(TGF)-b and laminin (LM)-111 significantly raised
the expression of matrix metalloproteinase
(MMP)-3.3 Here we extend our investigation to
determine whether other MMPs or their specific
tissue inhibitors of matrix proteases (TIMPs) also
respond to this mode of activation.
The activator protein (AP)-1, a heterodimer of
jun/fos proteins, was shown to play a crucial part
in the regulation of MMPs in fibroblasts,4 and co-
expression of MMP and c-fos was seen in
rheumatoid arthritis (RA) SF.5 TIMPs are regulated
by other transcription factors, including Egr-1.6 In
the cytokine-induced kinase pathways, phosphor-
ylation and nuclear translocation of transcription
factor nuclear factor (NF)-kB regulate the expression
of MMPs in SFs.7 8 We therefore hypothesised that
the LM-111- and TGF-b-activated expression of
MMPs and TIMPs could address transcription factors
such as AP-1 or Egr-1 and involve NF-kB activity as
well.
Co-stimulation of SFs by LM-111 in the presence
of TGF-b resulted in significant expression of
MMP-3 and MMP-10. No phosphorylation of
transcription factor NF-kB was observed and no
involvement of IL-1b and TNF-a detected. We
conclude that the attachment of SFs to LM-111 in
the presence of TGF-b is sufficient to induce
overexpression of MMP-3 and -10 by SFs.
MATERIALS AND METHODS
Cell culture
SFs were isolated from surgical samples of seven
patients with RA9 and eight patients with osteoar-
thritis, and expanded in vitro as described.3 Briefly,
the tissue was minced and degraded in collagenase/
phosphate-buffered saline. The fibroblasts were
expanded in DMEM complete medium. All studies
were approved by the local ethics committee.
Transcript analysis
In induction experiments, cells were stimulated for
24 h in the presence of 10 ng/ml recombinant
human TGF-b1 and/or in LM-111-coated flasks as
described recently.3 Gene expression was compared
with that in non-activated controls. RNA was
extracted from 106 SFs to generate cDNA.
Transcript quantities in SFs were determined by
qRT-PCR and normalised to GAPDH.
Recombinant DNA standards served as controls.
Protein analysis by sodium dodecyl sulphate–
polyacrylamide gel electrophoresis and
immunoblotting
Cells were incubated overnight on LM-111-coated
flasks (10 mg/ml) and stimulated by TGF-b1
(10 ng/ml) and/or LM-111 (10 mg/ml) for 60 min.
Cells without stimuli or activated by TGF-b1
served as controls. Cells were harvested, lysed
and subjected to immunoblot analysis as described
recently.3 The nylon membranes were probed
overnight at 4uC with affinity-purified rabbit
antisera (all from Santa Cruz (Santa Cruz, CA,
USA) or Cell Signalling (Danvers, MA, USA))
specific for total Egr-1 (C-19, 1:1000), total c-Fos
(H125, 1:1000), anti-total NF-kB (1:1000), or
phospho-NF-kB p-65 (1:1000). Blots were stripped
(1% sodium dodecyl sulphate/0.5% bME/TBE, 2 h,
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25uC), washed, blocked and incubated with affinity-purified
rabbit antiserum specific for b-actin (13E5, 1:1000) as loading
control. Binding of the primary antibodies was detected as
described.3
Detection of matrix metalloproteinases in cell culture
supernatants
The production of cytokines and MMPs was measured in SF
supernatants with a multiplexed immunoassay (Luminex,
Austin, TX, USA). Cells were activated for 24 h by the addition
of 10 ng/ml recombinant human TGF-b1, by attachment to
LM-111 or by attachment to LM-111 in the presence of 10 ng/
ml TGF-b1. Controls were incubated in normal tissue culture
flasks without stimuli. Supernatants were harvested and pre-
cleared by centrifugation, and aliquots mixed with fluoro-
chrome-labelled microbeads coated with antibodies reactive
with IL-1b, TNF-a or MMP-1, -2, -3, -7, -8, -9 and -13 (R&D
Systems, Abingdon, UK). To detect MMP-10, fluorochrome-
labelled microbeads were coated with affinity-purified mono-
clonal antibodies. Beads were washed, incubated with phycoer-
ythrin-labelled detection antibodies and analysed in a Luminex-
HTS device in flow cytometry mode as described by the
supplier. Serial dilutions of recombinant proteins served as
controls.
Statistics
A two-sided modified Student’s t-test was performed. Data sets
with p-values equal to or lower than 0.05, 0.01 or 0.001 were
considered statistically significant and marked accordingly (*, **,
***) in fig 1. Each data point represents the mean (SD) from
individual experiments using SFs from n different patients
(6(n(14).
RESULTS
Regulation of matrix metalloproteinase expression by
transforming growth factor-b and by attachment to laminin-111
Activation of SFs by TGF-b1 caused significant induction of
transcripts encoding TIMP-3 (mean 4.9 (SD 2.6), p(0.02),
MMP-3 (4.8-fold (2.7), p(0.001) and MMP-10 (3.25-fold (3.09),
p,0.04, fig 1A). Attachment of SFs to LM-111-coated flasks did
not induce significant responses (not shown). Activation of SFs
by TGF-b and LM-111 failed to further augment expression of
TIMP-3 (4.1 (1.6), p(0.001) compared with SFs activated by
TGF-b alone (fig 1B), but it significantly enhanced expression of
Figure 1 Induction of expression of matrix metalloproteinases (MMPs) by activated synovial fibroblasts (SFs). (A,B) The SFs were incubated in the
presence of 10 ng/ml transforming growth factor (TGF)-b in normal tissue culture flasks (n = 10 individuals, A) or in laminin (LM)-111-coated flasks in
the presence of 10 ng/ml TFG-b for 24 h (n = 14 individuals, B). Cells were harvested and gene expression patterns investigated by qRT-PCR,
comparing them with mock-treated controls. Each data point represents the mean induction index (SD) over non-activated controls ( = 1). (C,D) The
SFs were incubated in tissue culture flasks ( = control), in LM-111-coated flasks in the absence of TGF-b ( = LM-111), in tissue culture flasks in the
presence of 10 ng/ml TGF-b ( = TGF-b), or in LM-111-coated flasks in the presence of 10 ng/ml TGF-b ( = LM+TGF-b) at a starting density of 106 cells
per flask. After incubation for 24 h supernatants were harvested and concentrations of MMP-3 (fig 1C) and MMP-10 (fig 1D) were measured by
multiplexed analysis (Luminex). Data show the mean values (SD) from quadruplicate experiments using supernatants of seven SF populations.
Statistically significant differences between MMP expression in activated cells and that in controls are marked by asterisks. TIMP, specific tissue
inhibitors of matrix proteases.
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MMP-3 (12.34-fold (8), p,0.0001) and MMP-10 (11.68 (20),
p,0.05) (fig 1B). MMP-3 expression increased 2.55-fold
(p,0.01) and MMP-10 expression increased 3.6-fold compared
with cells activated by TGF-b alone. Transcripts encoding
MMP-1, -9 and -13 were significantly enhanced, but without
enhanced co-activation. No statistically significant difference in
induction of any of the MMPs or TIMPS investigated was
observed between SFs from RA and those from patients with
osteoarthritis. The expression of other TIMPs and MMPs
remained low or did not differ significantly from that of cells
induced by either LM-111 or TGF-b (fig 1B).
Induction of matrix metalloproteinase production by attachment
to laminin-111 in the presence of transforming growth factor-b
The SFs spontaneously secreted low amounts of MMP-3 (mean
9.89 (SD 10) ng/ml), but more MMP-3 was secreted upon
activation with TGF-b (mean 39 (28) ng/ml). This was signifi-
cantly enhanced by the attachment to LM-111 in presence of TGF-
b (mean 62.67 (42.5) ng/ml, p,0.05; fig 1C). Furthermore, SFs
spontaneously produced low levels of MMP-10 (mean 2.6 (1.4) ng/
ml), which was upregulated significantly by TGF-b (mean 31.36
(27.4) ng/ml p,0.02) and even more by attachment to LM-111 in
the presence of TGF-b (mean 54.27 (44.36) ng/ml, p,0.02; fig 1D).
Some MMP-9 was detected in supernatants of SFs without
stimulation (mean 35 (30) ng/ml); it was enhanced by attachment
to LM-111 in the presence of TGF-b (61.6 (14.8) ng/ml, p,0.02;
not shown). MMP-13 protein expression was not detected in any
of the investigated samples (detection limit 0.3 ng/ml, not
shown), and we saw no release of TNF-a (detection limit
0.5 pg/ml) or involvement of IL-1b (mean 13 pg/ml, not shown).
Expression of transcription factors Egr-1 and c-Fos without
activation of nuclear factor-kB
Transcription factors involved in this regulation of MMPs were
investigated 1 h after the stimulation of cells. Phosphorylation
of NF-kB was observed in SFs after activation with fetal calf
serum, but not after activation by either TGF-b, LM-111 or the
two stimuli together. Total NF-kB was detected in all extracts
(fig 2). The expression of Egr-1 and c-Fos was used as a positive
control and activation of SFs by TGF-b, LM-111 or both induced
enhanced expression of these transcription factors. Reprobing
the immunoblot with an antibody to b-actin served as loading
control (fig 2).
DISCUSSION
Attachment of SFs to LM-111 facilitated the TGF-b-induced
expression of MMP-3 but failed to induce a high MMP-1 response.3
Here we show that MMP-10, but no other MMP or TIMP
investigated, is significantly expressed in activated SFs as well.
IL-1b and TNF-a induce the expression of MMPs in
synoviocytes.2 In some patients with RA, however, radiological
progression is observed when biologically active TNF-a is
neutralised.10 As TGF-b levels were not reduced under this
treatment11 we hypothesised that it could be involved in the
regulation of MMPs. TGF-b utilises pathways to induce
expression of TIMP-1 and MMP-1 via AP-1 and SMAD12 and a
variety of MMPs.13 We recently showed that TGF-b and LM-111
utilise SMAD2, p38 and p42/44 MAP-kinases to activate
expression of MMP-3 independently of IL-1b or TNF-a.3 Both
IL-1b and TNF-a cause phosphorylation of NF-kB and its
translocation into the nuclei of activated cells.14 The data
presented here confirm that neither IL-1b nor TNF-a are
involved in this mode of co-activation of MMP-3 and MMP-
10. We did not detect phosphorylation of NF-kB in extracts of
TGF-b or LM-111 activated cells, either.
Stimulation of SFs by LM-111 and TGF-b is most likely not
an RA-specific mode of cellular activation as both RA SF and
osteoarthritis SF responded equally well to both stimuli.
Pathological integrin signalling contributes to proliferation of
cells, elevated MMP-3 expression, and even cancer due to
genomic instability.15 Our experimental set-up might reflect
such pathological matrix signalling due to elevated expression of
LMs in RA synovial tissue.16 It may also mimic changes in the
extracellular matrix stiffness, as fibrosis of synovial tissues
accompanies the RA pathology.17
In summary we show here that activation of SFs by
attachment to LM-111 in the presence of TGF-b activates
MMP-3 and MMP-10, and to some extent MMP-9. The IL-1b- and
TNF-a-associated NF-kB pathway is not involved in this mode of
activation.
Figure 2 Activation of transcription factors Egr-1, c-Fos and NF-kB by
transforming growth factor-b and laminin (LM)-111 signalling. The
synovial fibroblasts were incubated in LM-111-coated flasks and
activated by the addition of transforming growth factor-b (10 ng/ml) and
LM-111 (10 mg/ml, T+L, lane 1), or of LM-111 only (10 mg/ml, L, lane 2),
or they were incubated in normal cell culture flasks in the presence of
transforming growth factor-b only (10 ng/ml, T, lane 3) or in normal cell
culture flasks without stimulation as controls (c, lane 4). After 60 min of
stimulation cell extracts were then investigated for expression of Egr-1
(top) or c-Fos (below), for phosphorylation of NF-kB (middle), or for
expression of total NF-kB (below). Detection of b-actin served as a
loading control (bottom). The molecular weight of the proteins (kDa) is
marked on the left.
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